Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 22NIH 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 297Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Dihematoporphyrin Ether × Clear all
NCT02916745 2020-03-04

Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer

Concordia Laboratories Inc.

Phase 1 Completed
5 enrolled 30 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03344861 2020-01-13

Safety of PDT-Photofrin® Prior to Lung Surgery

Concordia Laboratories Inc.

Phase 1 Completed
10 enrolled 27 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡